Cargando…

Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer

BACKGROUND: Sarcopenia is prognostic for survival in patients with head and neck cancer (HNC). However, identification of this high-risk feature remains challenging without computed tomography (CT) imaging of the abdomen or thorax. Herein, we establish sarcopenia thresholds at the C3 level and deter...

Descripción completa

Detalles Bibliográficos
Autores principales: Olson, Brennan, Edwards, Jared, Degnin, Catherine, Santucci, Nicole, Buncke, Michelle, Hu, Jeffrey, Chen, Yiyi, Fuller, Clifton D., Geltzeiler, Mathew, Grossberg, Aaron J., Clayburgh, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882831/
https://www.ncbi.nlm.nih.gov/pubmed/35237517
http://dx.doi.org/10.3389/fonc.2022.812159
_version_ 1784659783695990784
author Olson, Brennan
Edwards, Jared
Degnin, Catherine
Santucci, Nicole
Buncke, Michelle
Hu, Jeffrey
Chen, Yiyi
Fuller, Clifton D.
Geltzeiler, Mathew
Grossberg, Aaron J.
Clayburgh, Daniel
author_facet Olson, Brennan
Edwards, Jared
Degnin, Catherine
Santucci, Nicole
Buncke, Michelle
Hu, Jeffrey
Chen, Yiyi
Fuller, Clifton D.
Geltzeiler, Mathew
Grossberg, Aaron J.
Clayburgh, Daniel
author_sort Olson, Brennan
collection PubMed
description BACKGROUND: Sarcopenia is prognostic for survival in patients with head and neck cancer (HNC). However, identification of this high-risk feature remains challenging without computed tomography (CT) imaging of the abdomen or thorax. Herein, we establish sarcopenia thresholds at the C3 level and determine if C3 sarcopenia is associated with survival in patients with HNC. METHODS: This retrospective cohort study was conducted in consecutive patients with a squamous cell carcinoma of the head and neck with cross-sectional abdominal or neck imaging within 60 days prior to treatment. Measurement of cross-sectional muscle area at L3 and C3 levels was performed from CT imaging. Primary study outcome was overall survival. RESULTS: Skeletal muscle area at C3 was strongly correlated with the L3 level in both men (n = 188; r = 0.77; p < 0.001) and women (n = 65; r = 0.80; p < 0.001), and C3 sarcopenia thresholds of 14.0 cm(2)/m(2) (men) and 11.1 cm(2)/m(2) (women) were best predictive of L3 sarcopenia thresholds. Applying these C3 thresholds to a cohort of patients with neck imaging alone revealed that C3 sarcopenia was independently associated with reduced overall survival in men (HR = 2.63; 95% CI, 1.79, 3.85) but not women (HR = 1.18, 95% CI, 0.76, 1.85). CONCLUSIONS: This study identifies sarcopenia thresholds at the C3 level that best predict L3 sarcopenia in men and women. In HNC, C3-defined sarcopenia is associated with poor survival outcomes in men, but not women, suggesting sarcopenia may differentially affect men and women with HNC.
format Online
Article
Text
id pubmed-8882831
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88828312022-03-01 Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer Olson, Brennan Edwards, Jared Degnin, Catherine Santucci, Nicole Buncke, Michelle Hu, Jeffrey Chen, Yiyi Fuller, Clifton D. Geltzeiler, Mathew Grossberg, Aaron J. Clayburgh, Daniel Front Oncol Oncology BACKGROUND: Sarcopenia is prognostic for survival in patients with head and neck cancer (HNC). However, identification of this high-risk feature remains challenging without computed tomography (CT) imaging of the abdomen or thorax. Herein, we establish sarcopenia thresholds at the C3 level and determine if C3 sarcopenia is associated with survival in patients with HNC. METHODS: This retrospective cohort study was conducted in consecutive patients with a squamous cell carcinoma of the head and neck with cross-sectional abdominal or neck imaging within 60 days prior to treatment. Measurement of cross-sectional muscle area at L3 and C3 levels was performed from CT imaging. Primary study outcome was overall survival. RESULTS: Skeletal muscle area at C3 was strongly correlated with the L3 level in both men (n = 188; r = 0.77; p < 0.001) and women (n = 65; r = 0.80; p < 0.001), and C3 sarcopenia thresholds of 14.0 cm(2)/m(2) (men) and 11.1 cm(2)/m(2) (women) were best predictive of L3 sarcopenia thresholds. Applying these C3 thresholds to a cohort of patients with neck imaging alone revealed that C3 sarcopenia was independently associated with reduced overall survival in men (HR = 2.63; 95% CI, 1.79, 3.85) but not women (HR = 1.18, 95% CI, 0.76, 1.85). CONCLUSIONS: This study identifies sarcopenia thresholds at the C3 level that best predict L3 sarcopenia in men and women. In HNC, C3-defined sarcopenia is associated with poor survival outcomes in men, but not women, suggesting sarcopenia may differentially affect men and women with HNC. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8882831/ /pubmed/35237517 http://dx.doi.org/10.3389/fonc.2022.812159 Text en Copyright © 2022 Olson, Edwards, Degnin, Santucci, Buncke, Hu, Chen, Fuller, Geltzeiler, Grossberg and Clayburgh https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Olson, Brennan
Edwards, Jared
Degnin, Catherine
Santucci, Nicole
Buncke, Michelle
Hu, Jeffrey
Chen, Yiyi
Fuller, Clifton D.
Geltzeiler, Mathew
Grossberg, Aaron J.
Clayburgh, Daniel
Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer
title Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer
title_full Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer
title_fullStr Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer
title_full_unstemmed Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer
title_short Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer
title_sort establishment and validation of pre-therapy cervical vertebrae muscle quantification as a prognostic marker of sarcopenia in patients with head and neck cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882831/
https://www.ncbi.nlm.nih.gov/pubmed/35237517
http://dx.doi.org/10.3389/fonc.2022.812159
work_keys_str_mv AT olsonbrennan establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer
AT edwardsjared establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer
AT degnincatherine establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer
AT santuccinicole establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer
AT bunckemichelle establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer
AT hujeffrey establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer
AT chenyiyi establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer
AT fullercliftond establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer
AT geltzeilermathew establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer
AT grossbergaaronj establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer
AT clayburghdaniel establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer